Dr Paul Kelly, an Australian physician and biotechnology entrepreneur, brings over 30 years of experience in developing and commercialising biomedical innovations in Europe, US and Australia. Prior to co-founding Sydney based Venture Capital Firm, OneVentures in 2010, Paul led numerous successful ventures in the US including Gemini Genomics, Agamatrix and Atomera. As founding partner at OneVentures he leads the Healthcare investment team. With a distinguished career in endocrinology at St Vincent's Hospital, Sydney, Paul holds medical and Doctorate degrees from the University of NSW. Serving on the boards of Garvan Institute of Medical Research, BiVacor, Prota Therapeutics, Clinical Genomics, Vaxxas, and Hatchtech, his expertise significantly contributes to the AEA. Paul joined the AEA Advisory Board as a member, bringing a breadth of seasoned expertise in medical science and enabling capabilities with skills in investment and research translation and commercialisation.